- In the second quarter of 2025, Eczacibasi Ilac reported a net income of 298.9 million liras.
- This represents a significant improvement from the previous year when the company faced a net loss of 462.5 million liras.
- Sales for the second quarter were recorded at 2.08 billion liras, indicating a decrease of 6.7% compared to the same period last year.
- There were no new buy, hold, or sell recommendations for Eczacibasi Ilac during this period.
A look at Eis Eczacibasi Ilac Ve Sinai Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 5 | |
| Dividend | 5 | |
| Growth | 4 | |
| Resilience | 4 | |
| Momentum | 3 | |
| OVERALL SMART SCORE | 4.2 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Based on the Smartkarma Smart Scores, Eis Eczacibasi Ilac Ve Sinai shows promising long-term prospects. The company scores highly in areas such as value and dividend, indicating strong fundamentals and potential for good returns for investors. With solid scores in growth and resilience as well, Eis Eczacibasi Ilac Ve Sinai seems well-positioned to weather market fluctuations and capitalize on growth opportunities.
Eis Eczacibasi Ilac Ve Sinai, a pharmaceutical and healthcare company, stands out for its robust performance across multiple factors. Known for producing pharmaceuticals, veterinary products, hospital equipment, and cosmetics, the company has a diverse product portfolio catering to various markets globally. With a focus on exports to regions such as the Middle East, Russian Federation, and EU countries, Eis Eczacibasi Ilac Ve Sinai demonstrates a strong international presence and potential for sustained growth.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
